Medical Science Liaison / Senior Medical Science Liaison
Acadia Pharmaceuticals- Full Time
- Junior (1 to 2 years)
Employment Type: Full-Time
GRAIL is a healthcare company pioneering new technologies to advance early cancer detection. Our mission is to detect cancer early, when it can be cured, and to change the trajectory of cancer mortality. We bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. GRAIL has built a multi-disciplinary organization of scientists, engineers, and physicians, utilizing next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges. GRAIL is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom.
The primary responsibility of the Houston-area, TX or Great Lakes MI/IN/OH/PA based Sr/Medical Science Liaison (MSL) supporting Galleri is to engage, educate, and support Galleri ordering providers and cancer diagnostic specialists, oncologists, Key Opinion Leaders (KOLs), and Health Care System (HCS) influencers. This involves providing them with the most current clinical and scientific materials supporting the appropriate implementation and utilization of the Galleri Multi-Cancer Early Detection (MCED) test.
This role will be accomplished through:
This position will ensure that all interactions and activities in the territories adhere to corporate and healthcare compliance guidance, including those related to clinical trials, scientific interactions with internal and external groups, and responses to unsolicited requests for medical/scientific information.
GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit grail.com.
Develops blood tests for early cancer detection
GRAIL focuses on improving cancer detection through advanced blood tests that identify cancer at its earliest stages, enhancing treatment success rates. The company utilizes high-intensity sequencing to analyze tumor genome data, employing algorithms and deep learning to extract actionable information for early cancer detection. GRAIL differentiates itself from competitors by its commitment to large-scale clinical studies that validate the effectiveness of its tests. The primary goal is to reduce global cancer mortality by enabling early diagnosis, making the disease more treatable.